Get the Stockscreener App
96.72
0.49%
0.47
After Hours:
96.77
0.05
+0.05%
Guardant Health Inc stock is traded at $96.72, with a volume of 2.73M.
It is up +0.49% in the last 24 hours and up +52.46% over the past month.
Guardant Health, based in Redwood City, California, is a leader in liquid-based cancer tests for clinical and research use. The company offers Guardant360 LDT, a liquid biopsy test for treatment selection in advanced-stage cancer, Guardant360 CDx, an FDA-approved companion diagnostic for several targeted therapies, and Guardant Omni, a broader gene panel for immuno-oncology research. In 2021, Guardant launched Reveal, a tumor-agnostic molecular residual disease test. In 2024, the company received US FDA approval for Shield, a liquid biopsy for colorectal cancer screening. Additionally, Guardant offers research development services such as regulatory approval consultancy and clinical trial referrals.
See More
Previous Close:
$96.25
Open:
$95.08
24h Volume:
2.73M
Relative Volume:
0.98
Market Cap:
$12.06B
Revenue:
$692.26M
Net Income/Loss:
$-512.41M
P/E Ratio:
-22.81
EPS:
-4.24
Net Cash Flow:
$-274.36M
1W Performance:
+3.98%
1M Performance:
+52.46%
6M Performance:
+143.38%
1Y Performance:
+238.30%
1-Day Range:
$92.54
$96.77
1-Week Range:
$88.88
$100.22
52-Week Range:
$28.20
$100.22
Guardant Health Inc Stock (GH) Company Profile
Name
Guardant Health Inc
Sector
Industry
Phone
855-698-8887
Address
3100 HANOVER STREET, PALO ALTO
Compare GH with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
GH
Guardant Health Inc
|
96.72 | 12.13B | 692.26M | -512.41M | -274.36M | -4.24 |
|
TMO
Thermo Fisher Scientific Inc
|
572.41 | 212.64B | 43.74B | 6.58B | 6.11B | 17.31 |
|
DHR
Danaher Corp
|
209.94 | 148.81B | 24.27B | 3.50B | 5.02B | 4.8589 |
|
IDXX
Idexx Laboratories Inc
|
708.45 | 56.99B | 4.17B | 1.03B | 940.22M | 12.61 |
|
A
Agilent Technologies Inc
|
146.74 | 41.81B | 6.79B | 1.22B | 1.09B | 4.2644 |
|
IQV
Iqvia Holdings Inc
|
210.46 | 35.91B | 15.90B | 1.28B | 2.21B | 7.2842 |
Guardant Health Inc Stock (GH) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Sep-25-25 | Upgrade | Wolfe Research | Peer Perform → Outperform |
| Sep-22-25 | Resumed | Wells Fargo | Overweight |
| Apr-10-25 | Initiated | Mizuho | Outperform |
| Jan-23-25 | Initiated | Barclays | Overweight |
| Jun-28-24 | Upgrade | Guggenheim | Neutral → Buy |
| Jun-03-24 | Resumed | Jefferies | Buy |
| Apr-24-24 | Resumed | Craig Hallum | Buy |
| Dec-14-23 | Initiated | Guggenheim | Neutral |
| Dec-13-23 | Initiated | Wolfe Research | Peer Perform |
| Nov-13-23 | Upgrade | Raymond James | Mkt Perform → Outperform |
| Sep-28-23 | Initiated | Bernstein | Outperform |
| Sep-27-23 | Upgrade | Piper Sandler | Neutral → Overweight |
| Jul-05-23 | Resumed | JP Morgan | Overweight |
| May-26-23 | Upgrade | Citigroup | Neutral → Buy |
| May-05-23 | Initiated | UBS | Buy |
| Mar-09-23 | Downgrade | Citigroup | Buy → Neutral |
| Jan-05-23 | Initiated | Scotiabank | Sector Outperform |
| Nov-01-22 | Downgrade | Piper Sandler | Overweight → Neutral |
| Oct-19-22 | Initiated | Craig Hallum | Buy |
| Oct-06-22 | Initiated | Stephens | Overweight |
| Aug-25-22 | Initiated | Credit Suisse | Outperform |
| Jun-03-22 | Initiated | Piper Sandler | Overweight |
| Apr-28-22 | Resumed | BTIG Research | Buy |
| Feb-24-22 | Reiterated | Canaccord Genuity | Buy |
| Feb-24-22 | Reiterated | Citigroup | Buy |
| Feb-24-22 | Reiterated | Cowen | Outperform |
| Feb-24-22 | Reiterated | Morgan Stanley | Overweight |
| Feb-24-22 | Reiterated | SVB Leerink | Outperform |
| Feb-24-22 | Reiterated | Stifel | Buy |
| Feb-24-22 | Reiterated | Wells Fargo | Overweight |
| Oct-15-21 | Resumed | Cowen | Outperform |
| Jun-15-21 | Initiated | Raymond James | Mkt Perform |
| Jun-03-21 | Initiated | Goldman | Buy |
| May-25-21 | Initiated | Wells Fargo | Overweight |
| Jan-11-21 | Initiated | Stifel | Buy |
| Sep-09-20 | Initiated | Morgan Stanley | Overweight |
| Jun-12-20 | Initiated | BTIG Research | Buy |
| Feb-21-20 | Initiated | Guggenheim | Buy |
| Jan-07-20 | Initiated | Citigroup | Buy |
| Aug-07-19 | Reiterated | Canaccord Genuity | Buy |
| Apr-16-19 | Initiated | Canaccord Genuity | Buy |
| Apr-10-19 | Upgrade | BofA/Merrill | Neutral → Buy |
| Feb-28-19 | Reiterated | BofA/Merrill | Neutral |
| Oct-29-18 | Initiated | BofA/Merrill | Neutral |
| Oct-29-18 | Initiated | JP Morgan | Overweight |
| Oct-29-18 | Initiated | William Blair | Outperform |
View All
Guardant Health Inc Stock (GH) Latest News
Relative strength of Guardant Health Inc. in sector analysis2025 Trade Ideas & Weekly Watchlist for Hot Stocks - newser.com
Why Guardant Health Inc. (5GH) stock could outperform next yearJuly 2025 Sentiment & Community Verified Trade Alerts - newser.com
Sentiment analysis tools applied to Guardant Health Inc.July 2025 Action & Community Consensus Stock Picks - newser.com
Is Guardant Health Inc. (5GH) stock a fit for income portfoliosMarket Trend Report & Reliable Entry Point Alerts - newser.com
Guardant Health to Participate in Upcoming Investor Conferences - The Joplin Globe
Key metrics from Guardant Health Inc.’s quarterly dataTrade Risk Report & Expert Approved Momentum Trade Ideas - newser.com
Will Guardant Health Inc. stock split again soonShort Setup & AI Enhanced Trade Execution Alerts - newser.com
Using AI based signals to follow Guardant Health Inc.Dip Buying & Risk Controlled Stock Alerts - newser.com
New Study Validates Guardant Reveal Blood Test’s Effectiveness in Monitoring Chemotherapy Response - BioSpace
Guardant Health Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - 01net
Can volume confirm reversal in Guardant Health Inc.Weekly Stock Analysis & Short-Term High Return Ideas - newser.com
How Guardant Health Inc. (5GH) stock correlates with oil marketsQuarterly Trade Summary & Free Verified High Yield Trade Plans - newser.com
Stocks making big moves yesterday: Clover Health, Rivian, Johnson Controls, Kratos, and Guardant Health - The Globe and Mail
New Study Validates Guardant Reveal Blood Test's Effectiveness in Monitoring Chemotherapy Response - MarketScreener
New study validates Guardant Reveal blood test's effectiveness in monitoring chemotherapy response - MarketScreener
Guardant Health (NASDAQ: GH) study shows 2.3-month median lead in progression detection - Stock Titan
Will Guardant Health Inc. stock go up soonJuly 2025 Retail & Free Safe Entry Trade Signal Reports - newser.com
How supply shortages influence Guardant Health Inc. (5GH) stock2025 Stock Rankings & Community Trade Idea Sharing Platform - newser.com
Guardant Health prices upsized $350 million convertible notes offering By Investing.com - Investing.com Nigeria
Guardant Health Inc. stock trendline breakdownJuly 2025 Big Picture & Low Drawdown Investment Ideas - newser.com
Can Guardant Health Inc. (5GH) stock deliver strong annual returnsTrade Analysis Report & Long-Term Safe Investment Plans - newser.com
Is Guardant Health Inc. (5GH) stock a top hedge fund pickMarket Movers & Low Drawdown Momentum Trade Ideas - newser.com
Guardant Health prices upsized $300 million common stock offering By Investing.com - Investing.com Nigeria
Why Guardant Health Inc. stock is recommended by analysts2025 Retail Activity & Real-Time Volume Triggers - newser.com
Guardant Health prices upsized $350 million convertible notes offering - Investing.com India
Guardant Health (GH) Blood Test Shows High Adherence for Colorec - GuruFocus
Guardant Health plans to offer $300 million in convertible notes By Investing.com - Investing.com Australia
Guardant Health launches $250 million common stock offering By Investing.com - Investing.com Australia
Guardant Health (Nasdaq: GH): 95% adherence in 20,000 Shield CRC blood screening patients - Stock Titan
Guardant Health Reaches New 52-Week High of $95.88, Up 207% - Markets Mojo
Guardant Health Shares Drop After $350M Notes, Stock Offering | 2025News and Statistics - IndexBox
Why Guardant Health (GH) Shares Are Sliding Today - Yahoo Finance
Guardant Health stock falls after pricing upsized convertible notes offering By Investing.com - Investing.com UK
Guardant Health stock falls after pricing upsized convertible notes offering - Investing.com
Market Participants Recognise Guardant Health, Inc.'s (NASDAQ:GH) Revenues Pushing Shares 56% Higher - 富途牛牛
GH: Key Insights on Recent Underwriting Developments - GuruFocus
How risky is Guardant Health Inc. stock now2025 Earnings Surprises & Stepwise Trade Signal Guides - newser.com
Guardant Health Ramps Up Fundraising With Stock And Note Offerings - Finimize
Guardant Health Prices Upsized Offering at $90 per Share - MarketScreener
Guardant Health prices upsized $350.0 million convertible senior notes offering - MarketScreener
Guardant Health Prices Upsized $350.0 Million Convertible Senior Notes Offering - The AI Journal
Guardant Health Announces Pricing of Upsized Public Offering of Common Stock - The AI Journal
Guardant Health Inc Stock (GH) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.69%
0.02%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):